Trials / Conditions / Cardiac Transplantation

Cardiac Transplantation

15 registered clinical trials studyying Cardiac Transplantation.

Status	Trial	Sponsor	Phase
Unknown	Anatomical and Functional Assessment of Ex-vivo Coronary Perfusion NCT05904678	Fondation Hôpital Saint-Joseph	—
Completed	Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation NCT03145441	Semmelweis University	N/A
Completed	Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs NCT02672683	Assistance Publique - Hôpitaux de Paris	—
Completed	Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the C NCT02255123	National Institute of Allergy and Infectious Diseases (NIAID)	—
Terminated	Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation NCT01235910	University of Colorado, Denver	Phase 4
Completed	Everolimus in de Novo Heart Transplant Recipients NCT01017029	Novartis Pharmaceuticals	Phase 4
Completed	CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calci NCT00799188	Hospices Civils de Lyon	Phase 3
Completed	Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal F NCT00716573	Hospices Civils de Lyon	Phase 4
Completed	Absolute Myocardial Perfusion Measurement in the Transplanted Heart NCT00414895	Insel Gruppe AG, University Hospital Bern	—
Terminated	Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC NCT00338455	Scios, Inc.	Phase 2
Active Not Recruiting	Oral Water Ingestion in Heart Transplant Patients NCT00581321	Satish R. Raj	N/A
Completed	Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients. NCT00170794	Novartis Pharmaceuticals	Phase 3
Terminated	Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients NCT00284531	Baylor College of Medicine	Phase 1 / Phase 2
Terminated	Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept NCT00166153	Emory University	N/A
Completed	Osteoporosis Prevention After Heart Transplant NCT00000412	Columbia University	Phase 3